Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Hepatoblastoma × pembrolizumab × Clear all

Phase

Status

Unknown 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 23 Melanoma 16 Breast Neoplasms 9 Neoplasms 8 Triple Negative Breast Neoplasms 7 Head and Neck Neoplasms 7 Squamous Cell Carcinoma of Head and Neck 6 Ovarian Neoplasms 6 Lung Neoplasms 6 Carcinoma, Hepatocellular 6 Stomach Neoplasms 5 Pancreatic Neoplasms 5 Neoplasm Metastasis 5 Colorectal Neoplasms 5 Carcinoma, Renal Cell 5 Uterine Cervical Neoplasms 3 Prostatic Neoplasms 3 Lymphoma 3 Liver Neoplasms 3 Kidney Neoplasms 3 Hodgkin Disease 3 Glioblastoma 3 Esophageal Neoplasms 3 Carcinoma 3 Neoplasms, Squamous Cell 2 Gastrointestinal Neoplasms 2 Fallopian Tube Neoplasms 2 Esophageal Squamous Cell Carcinoma 2 Endometrial Neoplasms 2 Carcinoma, Transitional Cell 2

Interventions

sintilimab 1 pembrolizumab 1 lenvatinib 1 camrelizumab 1 Vorinostat 1 Sugammadex 1 Neoadjuvant Therapy 1 Irinotecan 1 Immune Checkpoint Inhibitors 1 Granulocyte-Macrophage Colony-Stimulating Factor 1 Granulocyte Colony-Stimulating Factor 1 Drug Therapy 1 Doxorubicin 1 Cyclophosphamide 1 Cisplatin 1 Chemotherapy, Adjuvant 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05322187 2022-04-11

sPLENTY-pc

RenJi Hospital

Phase 2/3 Unknown

Gastrointestinal

Liver Neoplasms, Neoplasms, Hepatoblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡